Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 22, 2013 (14 years ago)

Irinotecan Hydrochloride Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Crystallization: Active pharmaceutical ingredient is precipitating in product solution.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

IRINOTECAN HYDROCHLORIDE INJECTION, 40 mg/2 mL (20 mg/mL), 2 mL Single Dose Vial, Rx only, Manufactured for: APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-193-02, UPC 3 63323 19302 7.

Affected NDC 63323-0193-02

Compare with the code on your package — it is the most precise check available.

Drug: Irinotecan

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Irinotecan Hydrochloride
NDC 63323-0193
20 mg/mL Injection, Solution
Intravenous
Fresenius Kabi USA, LLC Rx
Recalling firm
Fresenius Kabi USA LLC (FK USA)
NDC code
63323-193-02
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-915-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Irinotecan recalls

See all
Class II · Moderate risk

Irinotecan Hydrochloride Injection

CGMP Deviations: based on a Warning Letter received by the manufacturer of the recalled product for inadequate out-of specification investigations, complaint and the investigation conclusions.

Terminated Failed specification Areva Pharmaceuticals Inc NDC 59923-714-02 D-0270-2021
Class II · Moderate risk

Irinotecan HCL Injection

Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.

Terminated Packaging defect Hikma Pharmaceuticals USA Inc. NDC 0143-9583-01 D-1309-2020
Class II · Moderate risk

Irinotecan HCL Injection

Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.

Terminated Packaging defect Hikma Pharmaceuticals USA Inc. NDC 0143-9701-01 D-1308-2020

Other recalls by Fresenius Kabi USA LLC (FK USA)

All 2013 recalls